BioCryst Pharmaceuticals BCRX reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
BioCryst Pharmaceuticals beat estimated earnings by 5.88%, reporting an EPS of $-0.32 versus an estimate of $-0.34.
Revenue was up $15.57 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.03 which was followed by a 7.06% drop in the share price the next day.
Here's a look at BioCryst Pharmaceuticals's past performance:
| Quarter | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.37 | -0.3 | -0.29 | -0.24 |
| EPS Actual | -0.40 | -0.4 | -0.33 | -0.24 |
| Revenue Estimate | 51.36M | 50.56M | 39.38M | 28.48M |
| Revenue Actual | 49.92M | 47.16M | 40.99M | 49.96M |
To track all earnings releases for BioCryst Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
